1287 related articles for article (PubMed ID: 27821083)
41. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
42. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.
Dutton SJ; Kenealy N; Love SB; Wasan HS; Sharma RA;
BMC Cancer; 2014 Jul; 14():497. PubMed ID: 25011439
[TBL] [Abstract][Full Text] [Related]
43. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
[TBL] [Abstract][Full Text] [Related]
44. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
Yang H; Woo HY; Lee SK; Han JW; Jang B; Nam HC; Lee HL; Lee SW; Song DS; Song MJ; Oh JS; Chun HJ; Jang JW; Lozada A; Bae SH; Choi JY; Yoon SK
Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528
[TBL] [Abstract][Full Text] [Related]
45. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
[TBL] [Abstract][Full Text] [Related]
46. Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Schmidt L; op den Winkel M; Fischer K; Straub G; Rauch B; Paprottka PM; Göke B; Kolligs FT
Digestion; 2014; 90(4):219-28. PubMed ID: 25502689
[TBL] [Abstract][Full Text] [Related]
47. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.
Zhao JD; Liu J; Ren ZG; Gu K; Zhou ZH; Li WT; Chen Z; Xu ZY; Liu LM; Jiang GL
Radiat Oncol; 2010 Feb; 5():12. PubMed ID: 20149262
[TBL] [Abstract][Full Text] [Related]
48. Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Chow PK; Poon DY; Khin MW; Singh H; Han HS; Goh AS; Choo SP; Lai HK; Lo RH; Tay KH; Lim TG; Gandhi M; Tan SB; Soo KC;
PLoS One; 2014; 9(3):e90909. PubMed ID: 24614178
[TBL] [Abstract][Full Text] [Related]
49. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
[TBL] [Abstract][Full Text] [Related]
50. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
Kitajima T; Hatano E; Mitsunori Y; Taura K; Fujimoto Y; Mizumoto M; Okajima H; Kaido T; Minamiguchi S; Uemoto S
Clin J Gastroenterol; 2015 Oct; 8(5):300-5. PubMed ID: 26249525
[TBL] [Abstract][Full Text] [Related]
51. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
52. [Hepatocellular Carcinoma: New multimodal therapy concepts].
Schultheiß M; Bettinger D; Fichtner-Feigl S; Thimme R
Dtsch Med Wochenschr; 2018 Jun; 143(11):815-819. PubMed ID: 29807383
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
54. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Lorenzin D; Pravisani R; Leo CA; Bugiantella W; Soardo G; Carnelutti A; Umberto B; Risaliti A
Cancer Biother Radiopharm; 2016 Mar; 31(2):65-9. PubMed ID: 26986817
[TBL] [Abstract][Full Text] [Related]
55. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
56. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
57. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
[TBL] [Abstract][Full Text] [Related]
58. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
59. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
[TBL] [Abstract][Full Text] [Related]
60. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Sato Y; Nishiofuku H; Yasumoto T; Nakatsuka A; Matsuo K; Kodama Y; Okubo H; Abo D; Takaki H; Inaba Y; Yamakado K
J Vasc Interv Radiol; 2018 Aug; 29(8):1061-1067. PubMed ID: 29934260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
